Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models
- PMID: 12915382
- DOI: 10.1152/ajprenal.00191.2002
Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models
Abstract
Tubulointerstitial fibrosis is a hallmark feature of chronic renal injury. Specific therapies to control the progression of renal fibrosis toward end-stage renal failure are limited. Previous studies have demonstrated that expression of endogenous bone morphogenic protein-7 (BMP-7) is reduced in the kidneys of several inducible mouse models of acute and chronic renal disease and that administration of exogenous recombinant human BMP-7 (rhBMP-7) has a beneficial effect on kidney function. Here we report that treatment with rhBMP-7 leads to improved renal function, histology, and survival in mice deficient in the alpha3-chain of type IV collagen and MRL/MpJlpr/lpr lupus mice, two genetic models for chronic renal injury and fibrosis. Such therapeutic benefit is also associated with a significant decrease in the expression of profibrotic molecules, such as type I collagen and fibronectin, in renal fibroblasts. Additionally, rhBMP-7 induces expression of active matrix metalloproteinase-2, which is potentially important for removal of fibrotic matrix. Collectively, these studies provide further evidence for rhBMP-7 as an important bone-associated protein with protective function against renal pathology.
Similar articles
-
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.Nat Med. 2003 Jul;9(7):964-8. doi: 10.1038/nm888. Nat Med. 2003. PMID: 12808448
-
The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function.J Nephrol. 2003 Mar-Apr;16(2):179-85. J Nephrol. 2003. PMID: 12768064 Review.
-
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.Diabetes. 2007 Jul;56(7):1825-33. doi: 10.2337/db06-1226. Epub 2007 Apr 24. Diabetes. 2007. PMID: 17456853
-
Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice.Kidney Int. 2006 Jul;70(1):121-9. doi: 10.1038/sj.ki.5001521. Epub 2006 May 24. Kidney Int. 2006. PMID: 16723981
-
Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.J Nephrol. 2004 Jul-Aug;17(4):496-503. J Nephrol. 2004. PMID: 15372410 Review.
Cited by
-
A Current Landscape on Alport Syndrome Cases: Characterization, Therapy and Management Perspectives.Biomedicines. 2023 Oct 12;11(10):2762. doi: 10.3390/biomedicines11102762. Biomedicines. 2023. PMID: 37893135 Free PMC article. Review.
-
To Explore the Putative Molecular Targets of Diabetic Nephropathy and their Inhibition Utilizing Potential Phytocompounds.Curr Med Chem. 2024;31(24):3752-3790. doi: 10.2174/0929867330666230519112312. Curr Med Chem. 2024. PMID: 37211853 Review.
-
JLP/Foxk1/N-cadherin axis fosters a partial epithelial-mesenchymal transition state in epithelial tubular cells.iScience. 2023 Mar 14;26(4):106396. doi: 10.1016/j.isci.2023.106396. eCollection 2023 Apr 21. iScience. 2023. PMID: 37013185 Free PMC article.
-
PTEN-AKT pathway attenuates apoptosis and adverse remodeling in ponatinib-induced skeletal muscle toxicity following BMP-7 treatment.Physiol Rep. 2023 Mar;11(6):e15629. doi: 10.14814/phy2.15629. Physiol Rep. 2023. PMID: 36945866 Free PMC article.
-
Insights into bone morphogenetic proteins in cardiovascular diseases.Front Pharmacol. 2023 Feb 23;14:1125642. doi: 10.3389/fphar.2023.1125642. eCollection 2023. Front Pharmacol. 2023. PMID: 36909186 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical